Analysis of antigenic profiles of inactivated poliovirus vaccine and vaccine-derived polioviruses by block-ELISA method

Biologicals

Volumn 33, Issue 1, 2005, Pages 29-39

  Rezapkin, Gennady ^a   Martin, Javier ^a,b   Chumakov, Konstantin ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; D ANTIGEN; EPITOPE; IMMUNOGLOBULIN G ANTIBODY; MONOCLONAL ANTIBODY; ORAL POLIOMYELITIS VACCINE; POLIOMYELITIS VACCINE; POLYCLONAL ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS ANTIGEN;

ANTIBODY SPECIFICITY; ANTIGEN STRUCTURE; ANTIGENICITY; ARTICLE; CONJUGATION; CONTROLLED STUDY; DRUG POTENCY; DRUG STRUCTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; NONHUMAN; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RABBIT; VACCINE PRODUCTION; VIRUS STRAIN; WILD TYPE;

ORYCTOLAGUS CUNICULUS; POLIOVIRUS;

EID: 13844256956     PISSN: 10451056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biologicals.2004.11.001     Document Type: Article

References (42)

1. K. Hummeler, and V.V. Hamparian Studies on the complement fixing antigens of poliomyelitis. I. Demonstration of type and group specific antigens in native and heated viral preparations J Immunol 81 1958 499 505
2. A.J. Beale The D-antigen content in poliovaccine as a measure of potency Lancet 2 1961 1166 1168
3. B. Blondel, O. Akacem, R. Crainic, P. Couillin, and F. Horodniceanu Detection by monoclonal antibodies of an antigenic determinant critical for poliovirus neutralization present on VP1 and on heat-inactivated virions Virology 126 1983 707 710
4. C. Wychowski, S. van der Werf, O. Siffert, R. Crainic, P. Bruneau, and M. Girard A poliovirus type 1 neutralization epitope is located within amino acid residues 93 to 104 of viral capsid polypeptide VP1 EMBO J 2 1983 2019 2024
5. C.E. Fricks, J.P. Icenogle, and J.M. Hogle Trypsin sensitivity of the Sabin strain of type 1 poliovirus: cleavage sites in virions and related particles J Virol 54 1985 856 859
6. B. Blondel, R. Crainic, O. Fichot, G. Dufraisse, A. Candrea, and D. Diamond Mutations conferring resistance to neutralization with monoclonal antibodies in type 1 poliovirus can be located outside or inside the antibody-binding site J Virol 57 1986 81 90
7. J.P. Icenogle, P.D. Minor, M. Ferguson, and J.M. Hogle Modulation of humoral response to a 12-amino-acid site on the poliovirus virion J Virol 60 1986 297 301
8. P.D. Minor Antigenic structure of poliovirus Microbiol Sci 3 1986 141 144
9. A. Huovilainen, T. Hovi, L. Kinnunen, K. Takkinen, M. Ferguson, and P. Minor Evolution of poliovirus during an outbreak: sequential type 3 poliovirus isolates from several persons show shifts of neutralization determinants J Gen Virol 68 Pt 5 1987 1373 1378
10. P.D. Minor, M. Ferguson, A. Phillips, D.I. Magrath, A. Huovilainen, and T. Hovi Conservation in vivo of protease cleavage sites in antigenic sites of poliovirus J Gen Virol 68 Pt 7 1987 1857 1865
11. M. Roivainen, and T. Hovi Intestinal trypsin can significantly modify antigenic properties of polioviruses: implications for the use of inactivated poliovirus vaccine J Virol 61 1987 3749 3753
12. J.T. Stapleton, and S.M. Lemon Neutralization escape mutants define a dominant immunogenic neutralization site on hepatitis A virus J Virol 61 1987 491 498
13. A. Huovilainen, L. Kinnunen, M. Ferguson, and T. Hovi Antigenic variation among 173 strains of type 3 poliovirus isolated in Finland during the 1984 to 1985 outbreak J Gen Virol 69 Pt 8 1988 1941 1948
14. K. Wiegers, H. Uhlig, and R. Dernick Evidence for a complex structure of neutralization antigenic site I of poliovirus type 1 Mahoney J Virol 62 1988 1845 1848
15. J.M. Hogle, and D.J. Filman The antigenic structure of poliovirus Philos Trans R Soc Lond B Biol Sci 323 1989 467 478
16. P.D. Minor Antigenic structure of picornaviruses Curr Top Microbiol Immunol 161 1990 121 154
17. P.D. Minor, M. Ferguson, K. Katrak, D. Wood, A. John, and J. Howlett Antigenic structure of chimeras of type 1 and type 3 poliovirus involving antigenic site 1 J Gen Virol 71 Pt 11 1990 2543 2551
18. E.I. Budowsky Problems and prospects for preparation of killed antiviral vaccines Adv Virus Res 39 1991 255 290
19. P.D. Minor, M. Ferguson, K. Katrak, D. Wood, A. John, and J. Howlett Antigenic structure of chimeras of type 1 and type 3 polioviruses involving antigenic sites 2, 3 and 4 J Gen Virol 72 Pt 10 1991 2475 2481
20. M. Ferguson, D.J. Wood, and P.D. Minor Antigenic structure of poliovirus in inactivated vaccines J Gen Virol 74 Pt 4 1993 685 690
21. R. Ketterlinus, K. Wiegers, and R. Dernick Revertants of poliovirus escape mutants: new insights into antigenic structures Virology 192 1993 525 533
22. V. Patel, M. Ferguson, and P.D. Minor Antigenic sites on type 2 poliovirus Virology 192 1993 361 364
23. L.A. Sawyer, J. McInnis, and P. Albrecht Quantitation of D antigen content in inactivated poliovirus vaccine derived from wild-type or sabin strains Biologicals 21 1993 169 177
24. H.G. van der Avoort, B.P. Hull, T. Hovi, M.A. Pallansch, O.M. Kew, and R. Crainic Comparative study of five methods for intratypic differentiation of polioviruses J Clin Microbiol 33 1995 2562 2566
25. M.W. Wien, D.J. Filman, E.A. Stura, S. Guillot, F. Delpeyroux, and R. Crainic Structure of the complex between the Fab fragment of a neutralizing antibody for type 1 poliovirus and its viral epitope Nat Struct Biol 2 1995 232 243
26. D.J. Wood, A.B. Heath, and L.A. Sawyer A WHO collaborative study on assays of the antigenic content of inactivated poliovirus vaccines Biologicals 23 1995 83 94
27. L.A. Sawyer, D.J. Wood, M. Ferguson, R. Crainic, E.C. Beuvery, and J. McInnis Potency of wild-type or sabin trivalent inactivated poliovirus vaccine, by enzyme-linked immunosorbent assay using monoclonal antibiotics specific for each antigenic site Biologicals 25 1997 299 306
28. R.E. Taffs, Y.V. Chernokhvostova, E.M. Dragunsky, T. Nomura, K. Hioki, and E.C. Beuvery Inactivated poliovirus vaccine protects transgenic poliovirus receptor mice against type 3 poliovirus challenge J Infect Dis 175 1997 441 444
29. L. Fiore, D. Genovese, E. Diamanti, S. Catone, B. Ridolfi, and B. Ibrahimi Antigenic and molecular characterization of wild type 1 poliovirus causing outbreaks of poliomyelitis in Albania and neighboring countries in 1996 J Clin Microbiol 36 1998 1912 1918
30. K.M. Chumakov Molecular consistency monitoring of oral poliovirus vaccine and other live viral vaccines Dev Biol Stand 100 1999 61 74
31. J.H. Reimerink, H.G. van der Avoort, A.M. van Loon, and M.P. Koopmans Genetic basis for immunological aberrations in poliovirus Sabin serotype 3 strains imported in the Netherlands J Clin Microbiol 37 1999 2393 2398
32. CDC Public health dispatch: acute flaccid paralysis associated with circulating vaccine-derived polioviruses - Philippines MMWR Morb Mortality Wkly Rep 50 2001 874 875
33. Y. Doi, S. Abe, H. Yamamoto, H. Horie, H. Ohyama, and K. Satoh Progress with inactivated poliovirus vaccines derived from the Sabin strains Dev Biol (Basel) 105 2001 163 169
34. E.A. Cherkasova, E.A. Korotkova, M.L. Yakovenko, O.E. Ivanova, T.P. Eremeeva, and K.M. Chumakov Long-term circulation of vaccine-derived poliovirus that causes paralytic disease J Virol 76 2002 6791 6799
35. O. Kew, V. Morris-Glasgow, M. Landaverde, C. Burns, J. Shaw, and Z. Garib Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus Science 296 2002 356 359
36. WHO Paralytic poliomyelitis in Madagascar Wkly Epidemiol Rec 77 2002 241 242
37. Pediarix - a combined vaccine for infants Med Lett Drugs Ther 45 2003 37 38
38. FDA licensure of diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis B (recombinant), and poliovirus vaccine combined, (PEDIARIX) for use in infants MMWR Morb Mortality Wkly Rep 52 2003 203 204
39. E. Cherkasova, M. Laassri, V. Chizhikov, E. Korotkova, E. Dragunsky, and V.I. Agol Microarray analysis of evolution of RNA viruses: evidence of circulation of virulent highly divergent vaccine-derived polioviruses Proc Natl Acad Sci U S A 100 2003 9398 9403
40. J. Martin, G. Crossland, D.J. Wood, and P.D. Minor Characterization of formaldehyde-inactivated poliovirus preparations made from live-attenuated strains J Gen Virol 84 2003 1781 1788
41. Dragunsky E, Ivanov A, Wells V, Ivshina A, Rezapkin G, Abe S. Evaluation of immunogenicity and protective properties of inactivated poliovirus vaccines: a new surrogate method for predicting vaccine efficacy. J Virol, submitted for publication.
42. Rezapkin G, Dragunsky E, Chumakov K. Improved ELISA test for determination of potency of inactivated poliovirus vaccine (IPV), Biologicals, doi:10.1016/j.biologicals.2004.11.003.